Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical is viewed positively because its Q1 results showed broad-based growth and strong execution, with revenue of $760MM rising 26% y/y ex-fx, gross margin expanding to 69.2%, operating margin reaching 25.2%, adjusted EBITDA margin at 32.3%, and EPS increasing 65% y/y to $1.12, all while U.S. Spine delivered its third consecutive quarter of 10% y/y growth and trauma advanced more than 30%. The company’s outlook is further supported by management’s reiterated 2026 revenue guidance of $3.18-3.22B and raised EPS guidance of $4.70-4.80, which reflects durable margin expansion, synergy capture, operating leverage, and a business mix that is increasingly benefiting from share gains in a market growing only about 3%. Long-term fundamentals also look attractive because the Excelsius platform has a differentiated native design with nearly 130,000 robotic procedures to date, Enabling Technologies grew 21% y/y even as the company shifts toward more recurring leases and rentals, and international revenue is still targeted to grow 12-15% y/y, creating multiple paths for sustained top-line and bottom-line expansion.

Globus Medical is facing a fundamentally pressured outlook because its core spine and musculoskeletal franchise is exposed to intense competition from larger medical device peers such as MDT, SYK, and ZBH, any of which could take share and weaken pricing power, while staffing shortages, FX/macro headwinds, and slower-than-expected spine market growth add further uncertainty. Although the company recently reported revenue of $760 million, up 11.2% organically, and non-GAAP EPS of $1.12 versus $0.92 consensus, its growth is still concentrated in musculoskeletal solutions and more than half of revenue comes from the United States, leaving performance vulnerable to concentration risk and any disruption in its expanding international operations. In addition, the GMED/NuVasive merger and any related revenue dis-synergies or integration issues could impair Enabling Technologies momentum and margins, even as management’s 2026 revenue guidance of $3.18 billion to $3.22 billion and EPS guidance of $4.70 to $4.80 imply continued execution risk if growth and profitability fail to track expectations.